Inhibrx is a clinical-stage biotechnology company with a pipeline of novel biologic therapeutic candidates, developed using protein engineering and Co.'s proprietary single domain antibody, or sdAb, platform. Co. has four programs in ongoing Phase 1 clinical trials, three for the treatment of various cancers, and one for Alpha-1 Antitrypsin Deficiency. Co.'s most advanced therapeutic candidate, INBRX-109, is a tetravalent death receptor 5, or DR5, agonist being evaluated in patients diagnosed with chondrosarcoma and mesotheliom. INBRX-106 is a hexavalent OX40 agonist developed for patients with locally advanced or metastatic solid tumors. Co. is also developing INBRX-105 and INNBRX-101. The INBX stock yearly return is shown above.
The yearly return on the INBX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the INBX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|